CAJ | 학술논문

胰腺癌是恶性程度最高的肿瘤之一，进展迅速，预后极差。胰腺癌的传统单一治疗方法（如手术、放疗、化疗）因早期诊断率低、缺乏敏感性等限制性因素已达到治疗的瓶颈。近年来，胰腺癌的辅助治疗主要包括有大量数据支持的系统性全身治疗和少量数据支持的放化疗联合等。目前的研究焦点多集中于论证吉西他滨的基础上添加辅助药物（细胞毒性药或者靶向药物）的效果以及放化疗联合治疗是否能提高总生存率和怎样合理运用生物治疗。该文就胰腺癌辅助治疗的研究进展予以综述。
이선암시악성정도최고적종류지일，진전신속，예후겁차。이선암적전통단일치료방법（여수술、방료、화료）인조기진단솔저、결핍민감성등한제성인소이체도치료적병경。근년래，이선암적보조치료주요포괄유대량수거지지적계통성전신치료화소량수거지지적방화료연합등。목전적연구초점다집중우론증길서타빈적기출상첨가보조약물（세포독성약혹자파향약물）적효과이급방화료연합치료시부능제고총생존솔화즘양합리운용생물치료。해문취이선암보조치료적연구진전여이종술。
Pancreatic cancer is one of the most malignant tumors,with rapid progress and poor progno-sis.The traditional single treatments of pancreatic cancer-surgery,radiotherapy,chemotherapy have reached to the bottleneck,because the early diagnosis rate is low and lack of sensitivity.In recent years,adjuvant therapy for pancreas adenocarcinoma includes systemic therapy based on high level evidence and combined chemora-diotherapy based on less robust data.Current research focuses include the addition of a second agent,either cytotoxic or targeted agent, to gemcitabine and whether the utilization of combined chemoradiotherapy improves overall survival and the reasonable use of immuno-biological therapy.Here is to make a review of the research progress in the adjuvant therapy for pancreatic cancer.